The US Food and Drug Administration (FDA) has approved Eli Lilly’s and Boehringer Ingelheim’s Jentadueto XR (linagliptin and metformin hydrochloride extended-release) tablets for the treatment of Type 2 diabetes in adults. Jentadueto XR is the seventh new treatment from the Boehringer Ingelheim-Lilly Diabetes alliance to be approved by the FDA in the last five years. The companies formed the alliance in 2011.

Jentadueto XR combines 2.5 mg or 5 mg of linagliptin with 1000 mg of metformin. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by increasing hormones that stimulate the pancreas to produce more insulin and the liver to produce less glucose. Metformin, a commonly prescribed initial treatment for Type II diabetes, lowers glucose production by the liver and its absorption in the intestine.

Source: Eli Lilly and Company